What to Ask Your Clinician
Most people leave this appointment with the answer they were always going to get, because the questions asked were the ones that had only one available reply. Is this menopause? invites a yes or a no. Should I go on HRT? invites a verdict. Neither produces the thing you actually came for, which is a reasoned account of what is happening and what the options are.
The questions below are chosen for a narrower reason: each one has an answer that is specific to you, and each one is hard to answer with a generality. That is the whole trick. What to track beforehand is the other half of it.
Six questions that change the answer
"What else could this be, and what are you checking for?" The most important question on the list and the one most likely to be skipped. Thyroid dysfunction, iron deficiency, B12 deficiency and disordered glucose all produce this picture and all are more treatable than the transition. The answer tells you whether anything is being excluded or whether the transition is being assumed.
"What are all the options, including the ones that are not hormones?" Non-hormonal approaches exist for vasomotor symptoms, sleep and mood, and for some people they are the right first move. A conversation that goes straight to yes-or-no on hormone therapy has skipped a category.
"What in my particular history changes this?" A personal history of breast cancer, of blood clots, of stroke or certain cardiovascular conditions, of unexplained bleeding or liver disease genuinely changes the answer — sometimes to no, more often to a different route or a longer conversation. Migraine with aura, high blood pressure and a family history of clotting all matter without necessarily ruling anything out. You want to know which of yours is in which category.
"What should improve, and roughly by when — and what will not?" This sets an expectation you can check against, and it forces the limits into the open. Not everything about midlife is hormonal, and a clinician who names what will not change is giving you a better answer than one who does not.
"What would make you change or stop this?" The question that turns a prescription into a plan. It should produce something concrete: what is monitored, when it is reviewed, and what findings would alter the course.
"What happens if we do nothing?" Waiting is a real option and for some people the right one. It should be chosen against a realistic timescale rather than an assumed one — how long this actually lasts covers why that matters — and with the knowledge that one category of symptom, the genitourinary one, does not improve on its own.
How to ask about risk so the answer is usable
Risk is where these conversations most often go wrong in both directions — closed down by a warning that was never that specific, or waved away by a reassurance that was never that general. Three questions keep it honest.
"Can you give me that in absolute terms?" A relative figure — anything phrased as an increase of some percentage — is unusable without knowing what it is an increase on. The same finding expressed as how many additional cases occur in a group of women over a year is a number you can actually weigh. This is not a technicality: reporting the original findings in relative terms is the specific thing that did twenty years of damage, and the guide tells that story properly.
"Which preparation and which route is that number from?" Estrogen alone and estrogen with a progestogen are different exposures with different risk profiles, and taking something by mouth is not the same as absorbing it through the skin. A risk figure that does not specify which is being described is not yet an answer.
"How does that change for someone with my history and my age?" Population estimates are the starting point, not the conclusion. Time since the final period is one of the inputs people least expect to matter.
You do not have to argue. Asking for the absolute form of a number is a normal request and most clinicians will welcome it.
What to say when the conversation closes early
Three stock replies close this appointment prematurely. Each has a question that reopens it without turning it into a dispute.
"You're too young for that." → "What age would you expect this to start, and what would change your mind?" The transition commonly begins in the mid-to-late forties and the symptoms begin before the cycle changes. A reply that names no criteria is a reply about a model, not about you.
"Your hormone levels are normal." → "Given that levels fluctuate through the transition, what would a single result need to show to rule this in or out?" It cannot rule it in or out, which is the point — perimenopause is diagnosed on a pattern. Why one panel misleads sets out the reasoning.
"Come back when your periods stop." → "Symptoms are affecting my work and my sleep now. What can be done in the meantime?" Reframing from diagnosis to impact usually moves the conversation, because impact is the thing clinical decisions are actually made on.
If it still goes nowhere, asking for a second opinion or for a referral to a clinician with a specific interest in menopause is a reasonable and unremarkable request. So is asking for the reasoning to be written in the notes.
If you are already on something
Two questions that often go unasked for longer than they should.
"This is not working — what are the possibilities?" Something not working can mean several different things, and they have different answers. Saying it plainly, early, is more useful than waiting for the next scheduled review.
"Is what you are prescribing an FDA-approved product or a compounded preparation?" These are not the same thing, and you are entitled to know which you are being offered. FDA-approved products have been through review for safety, effectiveness and manufacturing consistency. Compounded preparations are made for an individual and have not been evaluated by the FDA in that way; there are recognized clinical reasons a compounded preparation may be used, but it is not an approved product with a different label, and nobody should describe it as equivalent to one. Ask which it is, and ask why that choice was made for you. Hormone questions answered covers the related question of what "bioidentical" does and does not mean.
Frequently asked questions
"What else could this be, and what are you checking for?" It is the one that determines whether anything treatable underneath the picture gets found.
Ask for the absolute form — how many additional cases in a group of women over a year, rather than a percentage increase. Then ask which preparation and route the figure describes. Both are ordinary requests.
Ask what age they would expect this to begin and what would change their assessment. The transition commonly starts in the mid-to-late forties, and symptoms usually begin before the cycle changes visibly.
Ask what a single result would need to show to rule the transition in or out. Hormone levels fluctuate through the transition, so one draw cannot settle it — the diagnosis is made on the pattern of symptoms, age and cycle history.
Yes, and it is unremarkable. Asking for a referral to a clinician with a particular interest in menopause is equally reasonable.
Yes. Approved products and compounded preparations are different things, and knowing which one is being proposed, and why, is part of an informed decision.
Where this fits in your plan
Bring a record, lead with what this is costing you, and ask the questions whose answers have to be about you. That is most of what makes this appointment go well.
Nothing on this page recommends a treatment or a decision. Whether anything is appropriate for you is a clinical judgment made after an assessment and against a history no page can see — and the long version of how that judgment is genuinely made is the menopause and HRT guide.
We measure first. Then we act.
References
- American College of Obstetricians and Gynecologists. Management of Menopausal Symptoms — Practice Bulletin.
- Office on Women's Health, U.S. Department of Health and Human Services. Menopause treatment.
- National Institute on Aging. What Is Menopause?
- U.S. Food and Drug Administration. Information for consumers on compounded drug products, including that compounded drugs are not FDA-approved.
- American College of Obstetricians and Gynecologists. Guidance on compounded bioidentical menopausal hormone therapy.
- Back toMenopause and Perimenopause
- Am I in perimenopause?Perimenopause is recognized on a pattern, not a blood test. What the pattern is, and how it is found when the calendar cannot help you.Read
- The symptoms nobody warns you aboutFrozen shoulder, dry eye, ringing ears, burning mouth, crawling skin, palpitations. What is reported, how firm the link is, and what still needs checking.Read
- How long it lastsThe transition and the symptoms run on different clocks, and both last longer than most people are told. What the long-term research found.Read
- What to track firstA record of the pattern is worth more than one hormone panel. What to write down, for how long, and how to present it so it can be acted on.Read
- The long versionWhat the transition does, how hormone therapy is actually decided, and the questions that come up once you are on it.Read
- How we work with womenHormone therapy, menopause, weight loss, sexual wellness and longevity.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.
It does not recommend any treatment and is not a reason to start, stop or change one. Compounded preparations are not FDA-approved products and are not described here as equivalent to them.